Evidence map›Paper›PMID 42380593›Full record

Articlenpj drug discovery2026

AI-guided competitive docking for virtual screening and compound efficacy prediction.

Manon Mirgaux, Valeria Barcelli, Adeline C Y Chua, Pablo Bifani, René Wintjens

Abstract read
In one paragraph

Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manon MirgauxUnit of Microbiology, Bioorganic and Macromolecular Chemistry, Department of Research in Drug Development, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium. manon.mirgaux@ulb.be.
Valeria BarcelliLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Adeline C Y ChuaA*STAR Infectious Diseases Laboratory, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Pablo BifaniLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. pablo.bifani@ntu.edu.sg.
René WintjensUnit of Microbiology, Bioorganic and Macromolecular Chemistry, Department of Research in Drug Development, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium. rene.wintjens@ulb.be.

Funding

Singapore, Ministry of Education, Start-Up Grant NRF-CG2025-CG02-IG2-001001
6 · The paper itself

Abstract

Machine learning has revolutionized protein structure and interaction prediction, yet its full potential for drug discovery is still emerging. In this study, we show that denoise diffusion-based co-folding methods-such as AlphaFold3 and Boltz-1/2-not only achieve highly accurate protein-ligand interaction predictions but can also separate active compounds from inactive ones. We introduce a simple and effective strategy, pairwise competitive docking, which ranks candidate molecules by directly comparing their relative binding to a protein's target site. Applied to 17 protein benchmark systems, the method generated rankings consistent with experimental trends, although the degree of agreement varied considerably by system, with concordance indices ranging from 0.52 (indicating no meaningful correlation) to 0.89 (indicating strong correlation). Notably, our rankings showed strong agreement with Boltz-2 affinity predictions, positioning our method as a practical alternative for inhibitor prioritization. Finally, we show how pairwise competitive docking can accelerate the identification of promising hits within a large chemical library and guide the de novo design of inhibitors with improved predicted potency. Collectively, these findings highlight how modern machine-learning models can make structure-based drug design faster, more reliable, and more cost-effective than relying solely on experimental workflows.

Identifiers

PMID42380593
PMCPMC13267107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.